No recent analyst price targets found for DNPUF.
Latest News for DNPUF
Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that it has enrolled the required number of participants in its pivotal Phase 2 monotherapy trial for enzomenib, an investigational, oral selective menin inhibitor for the treatment of relapsed/refractory acute leukemia with KMT2A rearrangement, to allow for interim analysis. Achieving this milestone will enable SMPA to obtain…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for DNPUF.
Senate Trading
No Senate trades found for DNPUF.
U.S. House Trading
No House trades found for DNPUF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.